Nakamura, Hiroshi

写真a

Affiliation

Graduate School of Business Administration ( Hiyoshi )

Position

Professor
Scopus Paper Info  
Paper Count: 6 Citation Count: 94 h-index: 4

Click to view the Scopus page. The data was downloaded from Scopus API in April 05, 2026, via http://api.elsevier.com and http://www.scopus.com .

Page Top ▲

Other Affiliation 【 Display / hide 】

  • Dean, Graduate School of Business Administration

Page Top ▲

Career 【 Display / hide 】

  • 1996.04
    -
    1998.03

    大学専任講師(大学院経営管理研究科附属ビジネス・スクール)

  • 1996.04
    -
    1998.03

    大学専任講師(大学院経営管理研究科)

  • 1998.04
    -
    Present

    大学助教授(大学院経営管理研究科附属ビジネス・スクール)

  • 1998.04
    -
    Present

    大学助教授(大学院経営管理研究科)

Page Top ▲

Academic Background 【 Display / hide 】

  • 1988.03

    Hitotsubashi University, Faculty of Economics

    University, Graduated

  • 1990.03

    Other, Graduate School, Division of Economics

    United States, Graduate School, Completed, Doctoral course

Page Top ▲
 

Books 【 Display / hide 】

  • オープン化戦略の成果と課題

    NAKAMURA HIROSHI,SAWADA NAOHIRO,ASAKAWA KAZUHIRO, 有斐閣, 2016

  • ライフサイエンス産業経済分析－経営と政策の共進的発展－

    NAKAMURA HIROSHI, 慶應義塾出版会, 2009

  • 日本製薬工業協会

    2000.03

  • アメリカ通商政策の悲劇

    NAKAMURA HIROSHI, 東洋経済新報社, 1996

  • 経済危機

    NAKAMURA HIROSHI, 東洋経済新報社, 1992

Page Top ▲

Papers 【 Display / hide 】

  • Approval Disparities for New Drugs in the US and Japan

    Kasahara S., Wakutsu N., Nakamura H.

    JAMA Network Open 8 ( 6 )  2025.06

  • An Empirical Analysis of Japan's Drug Development Lag Behind the United States

    Nakamura H., Wakutsu N., Murayama S., Suzuki T.

    Journal of Clinical Pharmacology 62 ( 7 ) 847 - 854 2022.07

    ISSN  00912700

    　View Summary

    The “drug lag” (ie, the approval lag for new drugs) hinders patients’ access to innovative new medicines. The drug lag was heavily debated in Japan from the late 2000s to the early 2010s. It consists of “development lag” (ie, the submission date lag for new drug applications) and “review lag” (ie, the difference in review periods). As the 2 lags have different causes and display significantly different recent trends in Japan, we focus on the development lag—in contrast with most previous literature—between Japan and the United States, based on a database we created for all new drugs from 2008 to 2018 using publicly available data sources. First, we found that Japan's development lag relative to the United States did not shrink in terms of the overall distribution rather than the median, which was the focus of most prior studies. Second, we examined the factors (product characteristics) that significantly affected the development lag and found that products that underwent multiregional clinical trials and those that were certified as “breakthrough therapies” in the United States had significantly shorter development lags with high robustness, whereas products receiving price premiums did not. Finally, we discussed the policy implications of these results. For instance, innovative new drugs that are presumed to receive price premiums require enhanced policy support for early application from the initial stages of clinical trials. It is also essential to promote information sharing regarding evaluations by foreign reviewing authorities for efficient use in the home country.

  • 医療保険財政負担軽減と研究開発インセンティブ低下抑制の両立に向けた政策検討における割引率の活用－新薬創出等加算のシミュレーションによる経済分析－

    NAKAMURA HIROSHIWAKUTSU NAOHIKOKAKIHARA HIROAKI

    (医療経済学会)   2016.09

    Accepted

  • グローバル経済の動向と経営環境：　2016 ―新たな経済リスクに備える－

    NAKAMURA HIROSHI

    ケース教材 (慶應義塾大学大学院経営管理研究科)   2016.07

    Single Work, Accepted

  • 薬剤費上昇抑制策に対して耐性を持つ企業への脱皮に向けて―「マクロレベルでの予見力」向上と「3つの限界」の克服に向けた施策の重要性―

    NAKAMURA HIROSHI

    国際医薬品情報 (国際商業出版)   ( 1058 )  2016.05

    Single Work

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • ヘルスケア関連分野における成長戦略と薬価制度

    NAKAMURA HIROSHI

    (医療経済研究機構)   2013.12

    Lecture material (seminar, tutorial, course, lecture, etc.), Single Work

Page Top ▲

Presentations 【 Display / hide 】

  • 再生医療へのヒト細胞提供に関する社会調査から見た一般人の意識変容と体制の検討

    NAKAMURA HIROSHIEGAMI MIME

    [Domestic presentation]  日本再生医療学会, 

    2017.03
    , 

    Oral presentation (general)

  • 医療を取り巻く経済環境の変化

    NAKAMURA HIROSHI

    石川県病院薬剤師会三者合同学術研修会, 

    2017.02
    , 

    Symposium, workshop panel (nominated)

  • アントレプレナーシップ

    NAKAMURA HIROSHI

    [Domestic presentation] 

    2017.01
    , 

    Symposium, workshop panel (nominated), 慶應大学

  • 製薬業界を取り巻く外部環境変化と勝ち残り戦略（予定）

    NAKAMURA HIROSHI

    2017.01
    , 

    ファルマ・ビジネス・アカデミー

  • 製薬業界を取り巻く外部環境変化

    NAKAMURA HIROSHI

    2017.01
    , 

    笠野興産

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • 日本経済政策学会学会賞（学術賞）

    2017.11, Japan Economic Policy Association, 「New NHI Drug-pricing System in Japan: Incentives for R&D and Budget Neutrality」共著（International Journal of Economic Policy Studies）

  • 医療経済賞

    NAKAMURA HIROSHI, 2006, 医療経済フォーラム, 診療報酬点数設定の透明化・適正化と医療機関の経営・オペレーション効率化に向けた長期的な診療報酬制度改革への一考察－「政策的割増分」の別建ておよび「出口」の明確化とヤードスティック競争原理の適用－

    Type of Award： Other

  • 医療経済賞

    2006, 医療経済フォーラム, 診療報酬点数設定の透明化・適正化と医療機関の経営・オペレーション効率化に向けた長期的な診療報酬制度改革への一考察

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • SEMINAR IN BUSINESS ENVIRONMENT

    2025

  • RESEARCH SEMINAR IN BUSINESS ENVIRONMENT

    2025

  • INDIVIDUAL RESEARCH C (EMBA)

    2025

  • INDIVIDUAL RESEARCH B (EMBA)

    2025

  • INDIVIDUAL RESEARCH A (EMBA)

    2025

display all >>

Page Top ▲